NCT04563273 - Clinical Study of BCG Vaccine for Intradermal Injection | Biotech Hunter

Enrollment

160

Participants

Timeline

Start Date

October 21, 2020

Primary Completion Date

October 30, 2022

Study Completion Date

October 30, 2022

Conditions

Tuberculosis

Interventions

BIOLOGICAL

BCG vaccine 1（0.025mg/0.1ml/person）

Intradermal injection of 0.025mg/0.1ml/person dose BCG.

BIOLOGICAL

BCG vaccine 2 （0.05mg/0.1ml/person）

Intradermal injection of 0.05mg/0.1ml/person dose BCG.

BIOLOGICAL

BCG vaccine 3（0.075mg/0.1ml/person）

Intradermal injection of 0.075mg/0.1ml/person dose BCG.

BIOLOGICAL

BCG vaccine 4 （0.075mg/0.1ml/person）

Intradermal injection of 0.075mg/0.1ml/person dose BCG.

BIOLOGICAL

Placebo of BCG vaccine （0.1ml/person）

Intradermal injection of 0.1ml/person dose Placebo.

Trial Locations (1)

Sichuan Center for Disease Control and Prevention, Chengdu

All Listed Sponsors

lead

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

INDUSTRY